Dual Immune Checkpoint Inhibition in Melanoma and PD-L1 Expression: The Jury Is Still Out.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 39374477.
- Also identified by DOI 10.1200/JCO-24-01572.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This comment discusses the use of PD-L1 as a biomarker to guide treatment decisions for metastatic melanoma.
Medical subject headings
- Melanoma
- B7-H1 Antigen
- Immune Checkpoint Inhibitors
- Biomarkers, Tumor